Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| REGENERON PHARMACEUTICALS, INC.REGN · Entity 2010 | Director · Bd. Co-Chair, President & CEO | December 31, 2025 | January 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
REGENERON PHARMACEUTICALS, INC.
Report date December 31, 2025 · Filed January 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 214,523 |
Ending reported balance
After 2025-12-31 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2025-12-31 · Exercise / conversion · Acquired 28,570 · Balance 243,093 Row 2 · 2025-12-31 · Tax withholding · Disposed 28,570 · Balance 214,523 |
| 2020 Performance Stock UnitsSEC Table II · derivative / convertible security | Direct | 595,077 |
Reported balance
After 2025-12-31 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2025-12-31 · Exercise / conversion · Disposed 28,570 · Balance 595,077 F1: Each performance restricted stock unit ("PSU") represents a contingent right to receive one share of Company stock. These PSUs were earned during the applicable five-year performance period and vested on December 31, 2025 but remain subject to a mandatory holding period of three years after vesting, which ends early upon the reporting person's death or disability or a change in control of the Company. |
| Common StockSEC Table I · non-derivative | IndirectBy 2024 GRAT | 127,484 |
Reported balance
Holding disclosure · report date 2025-12-31 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 127,484 |
| Common StockSEC Table I · non-derivative | IndirectBy 2025 GRAT | 300,000 |
Reported balance
Holding disclosure · report date 2025-12-31 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 300,000 |
| Common StockSEC Table I · non-derivative | IndirectBy 401(k) Plan | 5,989 |
Reported balance
Holding disclosure · report date 2025-12-31 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 5,989 |
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 39,985 |
Reported balance
Holding disclosure · report date 2025-12-31 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 39,985 |
Filing footnotes · ownership attribution and instrument terms
F1: Each performance restricted stock unit ("PSU") represents a contingent right to receive one share of Company stock. These PSUs were earned during the applicable five-year performance period and vested on December 31, 2025 but remain subject to a mandatory holding period of three years after vesting, which ends early upon the reporting person's death or disability or a change in control of the Company.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 12, 2019 Filed Dec 13, 2019 21:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 97,209 | $377.16 | $36,663,346.44 |
DisclosureSEC source: 0001237899-19-000031 · edgardoc.xml · nonDerivative · entry 4 SCHLEIFER LEONARD S · CIK 0001218629 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 474,499 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| December 12, 2019 Filed Dec 13, 2019 21:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 187,500 | $21.25 | $3,984,375.00 |
DisclosureSEC source: 0001237899-19-000031 · edgardoc.xml · nonDerivative · entry 3 SCHLEIFER LEONARD S · CIK 0001218629 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 571,708 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| December 12, 2019 Filed Dec 13, 2019 21:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 64,754 | $377.16 | $24,422,618.64 |
DisclosureSEC source: 0001237899-19-000031 · edgardoc.xml · nonDerivative · entry 2 SCHLEIFER LEONARD S · CIK 0001218629 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 384,208 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| December 12, 2019 Filed Dec 13, 2019 21:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 124,900 | $21.25 | $2,654,125.00 |
DisclosureSEC source: 0001237899-19-000031 · edgardoc.xml · nonDerivative · entry 1 SCHLEIFER LEONARD S · CIK 0001218629 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 448,962 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| December 11, 2019 Filed Dec 13, 2019 21:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantPerformance Stock Units · Derivative | 25,155 | $0.00 | $0.00 |
DisclosureSEC source: 0001237899-19-000031 · edgardoc.xml · derivative · entry 10 SCHLEIFER LEONARD S · CIK 0001218629 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,155 Underlying: Common Stock · 25,155 shares Expires not disclosed F4 · derivative.exercise_price: Each performance-based restricted stock unit ("PSU") represents the contingent right to receive one share of the issuer's common stock at vesting. The amount reported reflects the maximum number of PSUs that may vest based upon the achievement of certain performance metrics related to total shareholder return over four-year and/or five-year performance periods ending on December 11, 2023 and December 11, 2024, respectively. Between 50% and 225% of the target number of PSUs (i.e., between 50% and 225% of 11,180 PSUs) may vest upon achievement of predetermined total shareholder return percentages derived from compound annual growth rates of 5% to 15% for the applicable performance period. If none of the performance metrics are achieved at the conclusion of the performance periods, the award expires. F4 · derivative.exercise_date: Each performance-based restricted stock unit ("PSU") represents the contingent right to receive one share of the issuer's common stock at vesting. The amount reported reflects the maximum number of PSUs that may vest based upon the achievement of certain performance metrics related to total shareholder return over four-year and/or five-year performance periods ending on December 11, 2023 and December 11, 2024, respectively. Between 50% and 225% of the target number of PSUs (i.e., between 50% and 225% of 11,180 PSUs) may vest upon achievement of predetermined total shareholder return percentages derived from compound annual growth rates of 5% to 15% for the applicable performance period. If none of the performance metrics are achieved at the conclusion of the performance periods, the award expires. F4 · derivative.expiration_date: Each performance-based restricted stock unit ("PSU") represents the contingent right to receive one share of the issuer's common stock at vesting. The amount reported reflects the maximum number of PSUs that may vest based upon the achievement of certain performance metrics related to total shareholder return over four-year and/or five-year performance periods ending on December 11, 2023 and December 11, 2024, respectively. Between 50% and 225% of the target number of PSUs (i.e., between 50% and 225% of 11,180 PSUs) may vest upon achievement of predetermined total shareholder return percentages derived from compound annual growth rates of 5% to 15% for the applicable performance period. If none of the performance metrics are achieved at the conclusion of the performance periods, the award expires. Read SEC document |
| December 11, 2019 Filed Dec 13, 2019 21:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 81,278 | $0.00 Strike: $372.46 | $0.00 |
DisclosureSEC source: 0001237899-19-000031 · edgardoc.xml · derivative · entry 9 SCHLEIFER LEONARD S · CIK 0001218629 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,278 Underlying: Common Stock · 81,278 shares Expires 2029-12-11 F2 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| March 21, 2019 Filed Mar 22, 2019 20:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 100 | $0.00 Strike: $21.25 | $0.00 |
DisclosureSEC source: 0001708138-19-000008 · edgardoc.xml · derivative · entry 3 SCHLEIFER LEONARD S · CIK 0001218629 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 312,400 Underlying: Common Stock · 100 shares Expires 2019-12-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: With respect to 187,500 underlying shares, the option became exercisable on December 31, 2012, based upon the satisfaction by the company of certain performance criteria during the period ended December 31, 2012. With respect to 125,000 underlying shares, the stock option award vested in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| March 21, 2019 Filed Mar 22, 2019 20:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 100 | $21.25 | $2,125.00 |
DisclosureSEC source: 0001708138-19-000008 · edgardoc.xml · nonDerivative · entry 1 SCHLEIFER LEONARD S · CIK 0001218629 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 424,062 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 13, 2018 Filed Dec 14, 2018 21:19 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 125,000 | $0.00 Strike: $16.80 | $0.00 |
DisclosureSEC source: 0001237899-18-000022 · edgardoc.xml · derivative · entry 7 SCHLEIFER LEONARD S · CIK 0001218629 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 125,000 shares Expires 2018-12-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F2 · derivative.exercise_date: With respect to 187,500 underlying shares, the option became exercisable on December 31, 2011, based upon the satisfaction by the company of certain performance criteria during the period ended December 31, 2011. With respect to 125,000 underlying shares, the stock option award vested in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| December 13, 2018 Filed Dec 14, 2018 21:19 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 187,500 | $0.00 Strike: $16.80 | $0.00 |
DisclosureSEC source: 0001237899-18-000022 · edgardoc.xml · derivative · entry 6 SCHLEIFER LEONARD S · CIK 0001218629 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 187,500 shares Expires 2018-12-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F2 · derivative.exercise_date: With respect to 187,500 underlying shares, the option became exercisable on December 31, 2011, based upon the satisfaction by the company of certain performance criteria during the period ended December 31, 2011. With respect to 125,000 underlying shares, the stock option award vested in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| December 13, 2018 Filed Dec 14, 2018 21:19 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 64,052 | $377.31 | $24,167,460.12 |
DisclosureSEC source: 0001237899-18-000022 · edgardoc.xml · nonDerivative · entry 4 SCHLEIFER LEONARD S · CIK 0001218629 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 423,962 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| December 13, 2018 Filed Dec 14, 2018 21:19 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 125,000 | $16.80 | $2,100,000.00 |
DisclosureSEC source: 0001237899-18-000022 · edgardoc.xml · nonDerivative · entry 3 SCHLEIFER LEONARD S · CIK 0001218629 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 488,014 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| December 13, 2018 Filed Dec 14, 2018 21:19 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 96,079 | $377.31 | $36,251,567.49 |
DisclosureSEC source: 0001237899-18-000022 · edgardoc.xml · nonDerivative · entry 2 SCHLEIFER LEONARD S · CIK 0001218629 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 363,014 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| December 13, 2018 Filed Dec 14, 2018 21:19 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 187,500 | $16.80 | $3,150,000.00 |
DisclosureSEC source: 0001237899-18-000022 · edgardoc.xml · nonDerivative · entry 1 SCHLEIFER LEONARD S · CIK 0001218629 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 459,093 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| December 12, 2018 Filed Dec 14, 2018 21:19 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 129,013 | $0.00 Strike: $381.40 | $0.00 |
DisclosureSEC source: 0001237899-18-000022 · edgardoc.xml · derivative · entry 8 SCHLEIFER LEONARD S · CIK 0001218629 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,013 Underlying: Common Stock · 129,013 shares Expires 2028-12-12 F3 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| December 13, 2017 Filed Dec 13, 2017 22:17 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 250,000 | $0.00 Strike: $21.92 | $0.00 |
DisclosureSEC source: 0001237899-17-000033 · edgardoc.xml · derivative · entry 5 SCHLEIFER LEONARD S · CIK 0001218629 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 250,000 shares Expires 2017-12-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F2 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| December 13, 2017 Filed Dec 13, 2017 22:17 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 121,586 | $385.08 | $46,820,336.88 |
DisclosureSEC source: 0001237899-17-000033 · edgardoc.xml · nonDerivative · entry 3 SCHLEIFER LEONARD S · CIK 0001218629 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 271,593 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| December 13, 2017 Filed Dec 13, 2017 22:17 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 14,230 | $385.08 | $5,479,688.40 |
DisclosureSEC source: 0001237899-17-000033 · edgardoc.xml · nonDerivative · entry 2 SCHLEIFER LEONARD S · CIK 0001218629 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 393,179 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| December 13, 2017 Filed Dec 13, 2017 22:17 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 250,000 | $21.92 | $5,480,000.00 |
DisclosureSEC source: 0001237899-17-000033 · edgardoc.xml · nonDerivative · entry 1 SCHLEIFER LEONARD S · CIK 0001218629 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 407,409 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| December 12, 2017 Filed Dec 13, 2017 22:17 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 139,474 | $0.00 Strike: $378.98 | $0.00 |
DisclosureSEC source: 0001237899-17-000033 · edgardoc.xml · derivative · entry 6 SCHLEIFER LEONARD S · CIK 0001218629 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,474 Underlying: Common Stock · 139,474 shares Expires 2027-12-12 F2 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| December 16, 2016 Filed Dec 19, 2016 21:07 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 146,815 | $0.00 Strike: $381.92 | $0.00 |
DisclosureSEC source: 0001237899-16-000086 · edgardoc.xml · derivative · entry 6 SCHLEIFER LEONARD S · CIK 0001218629 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,815 Underlying: Common Stock · 146,815 shares Expires 2026-12-16 F2 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| December 15, 2016 Filed Dec 19, 2016 21:07 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 250,000 | $0.00 Strike: $20.32 | $0.00 |
DisclosureSEC source: 0001237899-16-000086 · edgardoc.xml · derivative · entry 5 SCHLEIFER LEONARD S · CIK 0001218629 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 250,000 shares Expires 2016-12-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F2 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| December 15, 2016 Filed Dec 19, 2016 21:07 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 122,032 | $380.09 | $46,383,142.88 |
DisclosureSEC source: 0001237899-16-000086 · edgardoc.xml · nonDerivative · entry 3 SCHLEIFER LEONARD S · CIK 0001218629 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 157,409 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| December 15, 2016 Filed Dec 19, 2016 21:07 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 13,365 | $380.09 | $5,079,902.85 |
DisclosureSEC source: 0001237899-16-000086 · edgardoc.xml · nonDerivative · entry 2 SCHLEIFER LEONARD S · CIK 0001218629 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 279,441 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| December 15, 2016 Filed Dec 19, 2016 21:07 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 250,000 | $20.32 | $5,080,000.00 |
DisclosureSEC source: 0001237899-16-000086 · edgardoc.xml · nonDerivative · entry 1 SCHLEIFER LEONARD S · CIK 0001218629 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 292,806 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.